PL2206719T3 - Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien - Google Patents

Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien

Info

Publication number: PL2206719T3
Authority: PL; Poland
Prior art keywords: diene; methods; androsta; benzimidazole; beta
Prior art date: 2005-03-02

Application number

PL10150763T

Other languages

English (en)

Polish (pl)

Inventor

Angela Brodie

Vincent Njar

Original Assignee

Univ Maryland

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-03-02

Filing date

2006-03-02

Publication date

2015-03-31

2006-03-02 Application filed by Univ Maryland filed Critical Univ Maryland

2015-03-31 Publication of PL2206719T3 publication Critical patent/PL2206719T3/pl

Links

PAFKTGFSEFKSQG-PAASFTFBSA-N Galeterone Chemical compound C1=NC2=CC=CC=C2N1C1=CC[C@H]2[C@H](CC=C3[C@@]4(CC[C@H](O)C3)C)[C@@H]4CC[C@@]21C PAFKTGFSEFKSQG-PAASFTFBSA-N 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
238000000034 method Methods 0.000 abstract 3
SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical class C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 abstract 2
KCTZOTUQSGYWLV-UHFFFAOYSA-N N1C=NC=C2N=CC=C21 Chemical class N1C=NC=C2N=CC=C21 KCTZOTUQSGYWLV-UHFFFAOYSA-N 0.000 abstract 2
102000001307 androgen receptors Human genes 0.000 abstract 2
108010080146 androgen receptors Proteins 0.000 abstract 2
150000001875 compounds Chemical class 0.000 abstract 2
230000003389 potentiating effect Effects 0.000 abstract 2
102000004190 Enzymes Human genes 0.000 abstract 1
108090000790 Enzymes Proteins 0.000 abstract 1
101100298362 Homo sapiens PPIG gene Proteins 0.000 abstract 1
206010060862 Prostate cancer Diseases 0.000 abstract 1
208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
239000005557 antagonist Substances 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
150000004891 diazines Chemical class 0.000 abstract 1
238000003379 elimination reaction Methods 0.000 abstract 1
102000056262 human PPIG Human genes 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
239000012038 nucleophile Substances 0.000 abstract 1
230000000269 nucleophilic effect Effects 0.000 abstract 1
238000010651 palladium-catalyzed cross coupling reaction Methods 0.000 abstract 1
230000003637 steroidlike Effects 0.000 abstract 1
238000006467 substitution reaction Methods 0.000 abstract 1
238000003786 synthesis reaction Methods 0.000 abstract 1
DBHSVKZZSWTSTN-UHFFFAOYSA-N tributyl(pyridazin-3-yl)stannane Chemical class CCCC[Sn](CCCC)(CCCC)C1=CC=CN=N1 DBHSVKZZSWTSTN-UHFFFAOYSA-N 0.000 abstract 1
125000002348 vinylic group Chemical group 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/003—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton not condensed
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Urology & Nephrology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PL10150763T 2005-03-02 2006-03-02 Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien PL2206719T3 (pl)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US65739005P	2005-03-02	2005-03-02
EP10150763.0A EP2206719B1 (en)	2005-03-02	2006-03-02	Pharmaceutical composition comprising 3-beta-hydroxy-17-(1-h-benzimidazole-1-yl)androsta-5,16-diene
EP06736460A EP1853619B1 (en)	2005-03-02	2006-03-02	3-beta-hydroxy-17-(1h-benzimidazol-1-yl)androsta-5,16-diene for use in the treatment of a prostate disease

Publications (1)

Publication Number	Publication Date
PL2206719T3 true PL2206719T3 (pl)	2015-03-31

Family

ID=36941503

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PL10150763T PL2206719T3 (pl)	2005-03-02	2006-03-02	Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
PL06736460T PL1853619T3 (pl)	2005-03-02	2006-03-02	3-beta-Hydroksy-17-(1H-benzimidazol-1-ilo)-androsta-5,16-dien do zastosowania do leczenia choroby prostaty

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PL06736460T PL1853619T3 (pl)	2005-03-02	2006-03-02	3-beta-Hydroksy-17-(1H-benzimidazol-1-ilo)-androsta-5,16-dien do zastosowania do leczenia choroby prostaty

Country Status (21)

Country	Link
US (1)	US7875599B2 (2)
EP (2)	EP1853619B1 (2)
JP (2)	JP5130453B2 (2)
KR (1)	KR101380959B1 (2)
CN (2)	CN103349664A (2)
AT (1)	ATE482969T1 (2)
AU (1)	AU2006218711B2 (2)
BR (1)	BRPI0607523A2 (2)
CA (1)	CA2599953C (2)
DE (1)	DE602006017175D1 (2)
DK (2)	DK1853619T3 (2)
EA (1)	EA019560B1 (2)
ES (2)	ES2528055T3 (2)
IL (3)	IL185608A (2)
MX (1)	MX2007010593A (2)
NZ (1)	NZ561571A (2)
PL (2)	PL2206719T3 (2)
PT (2)	PT1853619E (2)
SI (2)	SI1853619T1 (2)
WO (1)	WO2006093993A1 (2)
ZA (1)	ZA200708106B (2)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8569275B2 (en)	2002-08-28	2013-10-29	Harbor Therapeutics, Inc.	Steroids having 7-oxgen and 17-heteroaryl substitution
AU2006218711B2 (en) *	2005-03-02	2010-11-11	University Of Maryland, Baltimore	Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
GB2454118B (en)	2007-06-06	2010-06-02	Univ Maryland	Hdac inhibitors and hormone targeted drugs for the treatment of cancer
GB2470873A (en) *	2008-03-12	2010-12-08	Univ Maryland	Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitors in prostrate cancer
US20100048913A1 (en) *	2008-03-14	2010-02-25	Angela Brodie	Novel C-17-Heteroaryl Steroidal CYP17 Inhibitors/Antiandrogens;Synthesis In Vitro Biological Activities, Pharmacokinetics and Antitumor Activity
US20110118219A1 (en)	2008-03-25	2011-05-19	University Of Maryland, Baltimore	Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
US8785423B2 (en) *	2008-04-14	2014-07-22	University Of Maryland, Baltimore	Compositions and methods of inducing endoplasmic reticulum stress response for the treatment of cell proliferative diseases
US20110190323A1 (en)	2008-08-28	2011-08-04	President And Fellows Of Harvard College	Cortistatin analogues and syntheses thereof
US20100105700A1 (en) *	2008-10-28	2010-04-29	Lead Therapeutics, Inc.	Decahydro-1h-indenoquinolinone and decahydro-3h-cyclopentaphenanthridinone cyp17 inhibitors
WO2010091299A2 (en) *	2009-02-05	2010-08-12	Tokai Pharmaceuticals	Novel combination cancer therapies
CN102686600A (zh) *	2009-02-05	2012-09-19	托凯药业股份有限公司	甾体cyp17抑制剂/抗雄激素物质的新型药物前体
GB2479693B (en) *	2009-02-05	2014-04-09	Tokai Pharmaceuticals Inc	Steroidal CYP17 inhibitors and their use in the treatment of cancer and prostate hyperplasia
WO2010149755A1 (en)	2009-06-26	2010-12-29	Novartis Ag	1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
CA2770092A1 (en)	2009-08-07	2011-02-10	Tokai Pharmaceuticals, Inc.	Treatment of prostate cancer
WO2011059969A2 (en) *	2009-11-13	2011-05-19	Tokai Pharmaceuticals, Inc.	Mammalian metabolites of steroids
CA2782266A1 (en) *	2009-11-30	2011-06-03	Harbor Biosciences, Inc.	Anticancer compounds and screening method
JP2013537210A (ja)	2010-09-16	2013-09-30	ノバルティスアーゲー	１７α−ヒドロキシラーゼ／Ｃ１７，２０−リアーゼ阻害剤
EP2651916A2 (en) *	2010-12-16	2013-10-23	BioMarin Pharmaceutical Inc.	C-17-heteroaryl steroidal compounds as inhibitors of cyp11b, cyp17, and/or cyp21
US9029399B2 (en)	2011-04-28	2015-05-12	Novartis Ag	17α-hydroxylase/C17,20-lyase inhibitors
CN103813794A (zh) *	2011-07-18	2014-05-21	拓凯制药公司	用于治疗前列腺癌的新型组合物及方法
US20150005265A1 (en) *	2011-12-22	2015-01-01	Susan Stewart	Methods and compositions for combination therapy using p13k/mtor inhibitores
RU2015137617A (ru)	2013-03-14	2017-04-18	Юниверсити Оф Мэриленд, Балтимор Офис Оф Текнолоджи Трансфер	Агенты, подавляющие андрогенные рецепторы, и их применение
EP2991644B1 (en) *	2013-04-04	2020-03-25	University of Maryland, Baltimore	Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity
CN105636594A (zh)	2013-08-12	2016-06-01	托凯药业股份有限公司	使用雄激素靶向疗法用于治疗肿瘤性疾病的生物标记物
AU2014369834B2 (en)	2013-12-24	2018-12-20	President And Fellows Of Harvard College	Cortistatin analogues and syntheses and uses thereof
CN103694299A (zh) *	2014-01-13	2014-04-02	中国药科大学	甾体类雄激素受体抑制剂、其制备方法及其医药用途
CN105732759A (zh) *	2015-01-29	2016-07-06	苏州晶云药物科技有限公司	(3β)-17-(1H-苯并咪唑-1-基)雄甾-5，16-二烯-3-醇的盐及其制备方法
WO2016182932A1 (en)	2015-05-08	2016-11-17	President And Fellows Of Harvard College	Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en)	2015-07-01	2018-11-14	President and Fellows of Harvard College	Cortistatin analogues and syntheses and uses thereof
US10682362B2 (en)	2015-10-14	2020-06-16	Wayne State University	Treatments and diagnostics for cancers
IT201600121375A1 (it) *	2016-11-30	2018-05-30	Ind Chimica Srl	PROCESSO PER LA PREPARAZIONE DI 3ß-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
CH714173B1 (it) *	2016-08-08	2021-04-15	Ind Chimica Srl	Processo per la preparazione di 3ß-idrossi-17-(1H-benzimidazol-1-il)androsta-5,16-diene.
IT201600083406A1 (it) *	2016-08-08	2018-02-08	Ind Chimica Srl	PROCESSO PER LA PREPARAZIONE DI 3β-IDROSSI-17-(1H-BENZIMIDAZOL-1-IL)ANDROSTA-5,16-DIENE
AU2019222652B2 (en)	2018-02-13	2021-09-02	Dana-Farber Cancer Institute, Inc.	Cyclin-dependent kinase degraders and methods of use
US20200369715A1 (en) *	2018-02-13	2020-11-26	Dana-Farber Cancer Institute, Inc.	Cyclin-dependent kinase inhibitors and methods of use
EP4065111A4 (en)	2019-11-26	2023-09-20	Dana-Farber Cancer Institute, Inc.	Potent and selective azaindole inhibitors of cdk8 and cdk19

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA27440A (en)		1887-08-16	James T. Walsh	Art of making sheet metal cans, for packing meats, fruits, vegetables, etc.
CH621803A5 (2) *	1974-08-08	1981-02-27	Siphar Sa
US5604213A (en) *	1992-03-31	1997-02-18	British Technology Group Limited	17-substituted steroids useful in cancer treatment
US5994335A (en)	1997-10-17	1999-11-30	The University Of Maryland, Baltimore	17-azolyl steroids useful as androgen synthesis inhibitors
WO2005014023A1 (en)	2003-07-29	2005-02-17	Dompe' Pha.R.Ma S.P.A.	Pharmaceutical combination of g-csf and plgf useful for blood stem cell
AU2006218711B2 (en)	2005-03-02	2010-11-11	University Of Maryland, Baltimore	Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity

2006
- 2006-03-02 AU AU2006218711A patent/AU2006218711B2/en not_active Expired
- 2006-03-02 WO PCT/US2006/007143 patent/WO2006093993A1/en not_active Ceased
- 2006-03-02 EA EA200701872A patent/EA019560B1/ru not_active IP Right Cessation
- 2006-03-02 SI SI200630861T patent/SI1853619T1/sl unknown
- 2006-03-02 KR KR1020077022440A patent/KR101380959B1/ko not_active Expired - Fee Related
- 2006-03-02 EP EP06736460A patent/EP1853619B1/en not_active Expired - Lifetime
- 2006-03-02 PT PT06736460T patent/PT1853619E/pt unknown
- 2006-03-02 PL PL10150763T patent/PL2206719T3/pl unknown
- 2006-03-02 CN CN2013101036754A patent/CN103349664A/zh active Pending
- 2006-03-02 SI SI200631883T patent/SI2206719T1/sl unknown
- 2006-03-02 CA CA2599953A patent/CA2599953C/en not_active Expired - Lifetime
- 2006-03-02 CN CNA2006800064632A patent/CN101155823A/zh active Pending
- 2006-03-02 PL PL06736460T patent/PL1853619T3/pl unknown
- 2006-03-02 JP JP2007558143A patent/JP5130453B2/ja not_active Expired - Lifetime
- 2006-03-02 DK DK06736460.4T patent/DK1853619T3/da active
- 2006-03-02 NZ NZ561571A patent/NZ561571A/en not_active IP Right Cessation
- 2006-03-02 AT AT06736460T patent/ATE482969T1/de active
- 2006-03-02 ES ES10150763.0T patent/ES2528055T3/es not_active Expired - Lifetime
- 2006-03-02 EP EP10150763.0A patent/EP2206719B1/en not_active Expired - Lifetime
- 2006-03-02 DK DK10150763.0T patent/DK2206719T3/en active
- 2006-03-02 MX MX2007010593A patent/MX2007010593A/es active IP Right Grant
- 2006-03-02 ES ES06736460T patent/ES2353413T3/es not_active Expired - Lifetime
- 2006-03-02 DE DE602006017175T patent/DE602006017175D1/de not_active Expired - Lifetime
- 2006-03-02 US US11/817,550 patent/US7875599B2/en active Active
- 2006-03-02 BR BRPI0607523-1A patent/BRPI0607523A2/pt not_active IP Right Cessation
- 2006-03-02 PT PT101507630T patent/PT2206719E/pt unknown
2007
- 2007-08-30 IL IL185608A patent/IL185608A/en not_active IP Right Cessation
- 2007-09-20 ZA ZA200708106A patent/ZA200708106B/xx unknown
2011
- 2011-01-06 IL IL210480A patent/IL210480A/en not_active IP Right Cessation
- 2011-01-06 IL IL210478A patent/IL210478A0/en unknown
2012
- 2012-09-06 JP JP2012196525A patent/JP5613206B2/ja not_active Expired - Lifetime

Also Published As

Publication number	Publication date
EP1853619A1 (en)	2007-11-14
PT2206719E (pt)	2015-02-05
DK1853619T3 (da)	2011-01-10
EP1853619B1 (en)	2010-09-29
IL210480A0 (en)	2011-03-31
PL1853619T3 (pl)	2011-03-31
DK2206719T3 (en)	2015-01-26
JP5613206B2 (ja)	2014-10-22
IL210480A (en)	2015-06-30
CN101155823A (zh)	2008-04-02
EA019560B1 (ru)	2014-04-30
US20080280864A1 (en)	2008-11-13
MX2007010593A (es)	2008-02-20
KR101380959B1 (ko)	2014-04-04
EP1853619A4 (en)	2009-08-26
JP2008536807A (ja)	2008-09-11
AU2006218711A2 (en)	2006-09-08
NZ561571A (en)	2009-09-25
JP5130453B2 (ja)	2013-01-30
ES2353413T3 (es)	2011-03-01
DE602006017175D1 (de)	2010-11-11
ES2528055T3 (es)	2015-02-03
HK1115387A1 (en)	2008-11-28
SI1853619T1 (sl)	2011-01-31
EP2206719B1 (en)	2014-10-22
AU2006218711A1 (en)	2006-09-08
IL185608A0 (en)	2008-01-06
WO2006093993A1 (en)	2006-09-08
EP2206719A2 (en)	2010-07-14
EA200701872A1 (ru)	2008-06-30
AU2006218711B2 (en)	2010-11-11
KR20070120119A (ko)	2007-12-21
IL185608A (en)	2016-06-30
CA2599953C (en)	2013-08-13
BRPI0607523A2 (pt)	2009-09-08
JP2012255026A (ja)	2012-12-27
CN103349664A (zh)	2013-10-16
US7875599B2 (en)	2011-01-25
ZA200708106B (en)	2008-12-31
EP2206719A3 (en)	2011-01-05
IL210478A0 (en)	2011-03-31
SI2206719T1 (sl)	2015-03-31
CA2599953A1 (en)	2006-09-08
PT1853619E (pt)	2011-01-03
ATE482969T1 (de)	2010-10-15

Publication	Publication Date	Title
PL2206719T3 (pl)	2015-03-31	Kompozycja farmaceutyczna zawierająca 3-beta-hydroksy-17-(1-h-benzimidazol-1-il)androsta-5,16-dien
PT1353672E (pt)	2008-01-11	Síntese da 4-amino talidomida enantiómeros
EP2966065A3 (en)	2016-03-02	Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2007087548A3 (en)	2007-12-13	Chemical compounds
SI1934174T1 (sl)	2011-08-31	Inhibitorji MEK in postopki za njihovo uporabo
MX2009003876A (es)	2009-05-11	Uso de compuestos de espiro-oxindol como agentes terapeuticos.
WO2009120565A3 (en)	2010-03-04	Novel prodrugs of c-17-heteroaryl steroidal cyp17 inhibitors/antiandrogens: synthesis, in vitro biological activities, pharmacokinetics and antitumor activity
NO20076319L (no)	2007-12-07	Farmasoytiske sammensetninger av et neuroaktivt steroid og anvendelse derav
AU2010210422A8 (en)	2011-08-25	Novel prodrugs of steroidal CYP17 inhibitors/antiandrogens
GEP20115213B (en)	2011-05-10	Thienopyrimidinone derivatives as melanin concentrating hormone receptor-1 antagonists
MXPA06009475A (es)	2007-05-15	Derivados de quinazolina y usos terapeuticos de los mismos.
TW200833698A (en)	2008-08-16	Spiroheterocyclic compounds and their uses as therapeutic agents
WO2005077968A8 (en)	2006-11-16	17-methylene-or 17 - spiro - cyclopropane 7 - substituted estra - 1, 3, 5 (10) - triene derivatives with anti - estrogenic activity
WO2005103010A3 (en)	2006-03-02	Pyrazole derivatives useful for the treatment of cancer
WO2008011539A3 (en)	2008-04-17	Anesthetic compounds
CY1115910T1 (el)	2017-01-25	ΦΑΡΜΑΚΕΥΤΙΚΗ ΣΥΝΘΕΣΗ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΕΙ 3-BETA-HYDROXY-17-(l-HBENZIMIDAZOLE-1-YL)ANDROSΤΑ-5,16-DIENE
UA93198C2 (ru)	2011-01-25	Производные пиразола, способ их получения, их применения, фармацевтическая композиция (варианты) и способ лечения злокачественного новообразования (варианты)
TW200603812A (en)	2006-02-01	D-homo-17-chlor-16(17)-ene steroids
TW200504044A (en)	2005-02-01	Methods for preparing derivatives of fungicidal iodochromones and intermediate compounds
TW200740442A (en)	2007-11-01	Therapeutic agent for hypertension
UA96742C2 (en)	2011-12-12	Mek inhibitors and use thereof